Repository logo
 

Mechanisms that clear mutations drive field cancerization in mammary tissue

Published version
Peer-reviewed

Repository DOI


Change log

Abstract

AbstractOncogenic mutations are abundant in the tissues of healthy individuals, but rarely form tumours1–3. Yet, the underlying protection mechanisms are largely unknown. To resolve these mechanisms in mouse mammary tissue, we use lineage tracing to map the fate of wild-type and Brca1−/−;Trp53−/− cells, and find that both follow a similar pattern of loss and spread within ducts. Clonal analysis reveals that ducts consist of small repetitive units of self-renewing cells that give rise to short-lived descendants. This offers a first layer of protection as any descendants, including oncogenic mutant cells, are constantly lost, thereby limiting the spread of mutations to a single stem cell-descendant unit. Local tissue remodelling during consecutive oestrous cycles leads to the cooperative and stochastic loss and replacement of self-renewing cells. This process provides a second layer of protection, leading to the elimination of most mutant clones while enabling the minority that by chance survive to expand beyond the stem cell-descendant unit. This leads to fields of mutant cells spanning large parts of the epithelial network, predisposing it for transformation. Eventually, clone expansion becomes restrained by the geometry of the ducts, providing a third layer of protection. Together, these mechanisms act to eliminate most cells that acquire somatic mutations at the expense of driving the accelerated expansion of a minority of cells, which can colonize large areas, leading to field cancerization.

Description

Acknowledgements: We thank the laboratories of van Rheenen and Scheele for critically reading the manuscript, and the Netherlands Cancer Institute (NKI) Animal facility, NKI BioImaging facility and the NKI genomics core facility for their technical support. This work was supported by the Boehringer Ingelheim Foundation (PhD Fellowship to C.L.G.J.S.), a Federation of European Biochemical Societies excellence award (to C.L.G.J.S.), the Research Foundation Flanders (PhD grant fundamental research no. 11L7222N to M.C.), EMBO (postdoctoral fellowship grant nos. ALTF 452-2019 to H.A.M. and ALTF 1035-2020 to C.L.G.J.S.) and the European Research Council (consolidator grant no. 648804 to J.v.R.), the Doctor Josef Steiner Foundation (to J.v.R.), the Netherlands Organization of Scientific Research (NWO) (Vici grant no. 09150182110004 to J.v.R., and Veni grant no. 09150161910151 to H.A.M.) and a joint grant of the Cancer Research UK and KWF Kankerbestrijding (ref. C38317/A24043). B.D.S. acknowledges funding from the Royal Society E.P. Abraham Research Professorship (grant nos. RP\R1\180165 and RSRP\R\231004) and Wellcome (grant nos. 098357/Z/12/Z and 219478/Z/19/Z). We regret that we could not cite all the important contributions in this field due to the constraint of being limited to citing only 60 studies. This research was funded, in part, by the Wellcome Trust (098357/Z/12/Z and 219478/Z/19/Z). For the purpose of Open Access, the authors have applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.

Keywords

Journal Title

Nature

Conference Name

Journal ISSN

0028-0836
1476-4687

Volume Title

633

Publisher

Springer Science and Business Media LLC

Rights and licensing

Except where otherwised noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/